SYNTHESIS & EVAL OF 1,5,6 TRIAZACHRYSENE & 5,6,11 TRIAZACHRYSENE DERIVATIVES

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 我们的主要研究兴趣是发现和开发新药。本课题组近年来一直致力于非喜树碱类拓扑异构酶I靶向抗肿瘤药物的设计与合成。已经鉴定了几种有效的拓扑异构酶I靶向剂。研究正在进行中，以确定这些化合物中更有前途的候选人发展到临床。最近，在我们的实验室进行了研究，以开发代理，将选择性地结合和稳定G-四链体DNA。我们目前正在探索这些G-四链体稳定剂在癌症化疗中的前景和全部潜力。此外，我们的研究小组已经开始研究发现新的先导化合物，用于开发同工酶特异性拓扑异构酶II靶向药物，用于未来开发这类癌症化疗药物中的改进临床药物。 更多信息请访问http://medchem.rutgers.edu/lavoie.shtml

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Our primary research interests are in the discovery and the development of novel pharmaceuticals. For several years our research group has focused on the design and synthesis of novel non-camptothecin topoisomerase I-targeting antitumor agents. Several potent topoisomerase I-targeting agents have been identified. Studies are in progress to identify among these compounds the more promising candidates for development into the clinic. Recently, studies in our laboratory have been undertaken to develop agents that will selectively bind and stabilize G-quadruplex DNA. We are presently exploring the promise and full potential of these G-quadruplex stabilizers in cancer chemotherapy. In addition, our research group has initiated research into the discovery of new lead compounds for the development of isozyme specific topoisomerase II-targeting agents for the future development of an improved clinical agent within this class of cancer chemotherapeutic agents. See more at http://medchem.rutgers.edu/lavoie.shtml